Related Experiment Video
Updated: Jul 17, 2026
07:10
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
QT interval correction in patients with cirrhosis
Andrea Zambruni1, Antonio Di Micoli, Alessandro Lubisco
1Department of Internal Medicine, Cardioangiology and Hepatology, Policlinico S. Orsola-Malpighi Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Journal of Cardiovascular Electrophysiology
|January 19, 2007
Summary
A new formula for correcting the QT interval in cirrhosis patients is proposed. This avoids misleading results from Bazett's formula, improving cardiac risk assessment and drug effect evaluation.
Area of Science:
- Cardiology
- Electrophysiology
- Hepatology
Background:
- QT interval prolongation is a common electrophysiological abnormality in cirrhosis patients.
- Existing QT correction formulas, like Bazett's, may be misleading due to over-correction and rate-dependency.
- A population-specific formula is needed for accurate QT interval assessment in cirrhosis.
Purpose of the Study:
- To analyze the QT-RR relationship in cirrhotic patients.
- To derive a population-specific QT correction formula for cirrhosis.
- To compare the derived formula with existing QT correction methods.
Main Methods:
- Enrolled 100 cirrhotic patients and 53 healthy controls.
- Analyzed QT-RR relationship using five regression models to derive a population-specific equation.
- Calculated corrected QT (QTc) using derived and standard formulas (Bazett, Fridericia, Framingham, Hodges) and assessed rate-independence.
Main Results:
- The derived power equation "QT = 453.65 x RR1/3.02" best described the QT-RR relationship (R2 = 0.41).
- Bazett's formula yielded the longest QTc and remained significantly influenced by RR interval (R = -0.39).
- The derived formula resulted in a QTc value independent of RR interval (R = -0.014).
Conclusions:
- Bazett's correction formula should be avoided in cirrhosis patients due to rate-dependency and potential for misleading results.
- The derived population-specific formula or Fridericia's formula can be reliably used for QTc assessment in cirrhosis.
- Accurate QTc assessment is crucial for preoperative cardiac risk and drug effect evaluation in cirrhotic patients.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:28Esophageal Varices-II: Clinical Features and Management
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...